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Pancreatic ductal adenocarcinoma (PDAC) is one of
the most deadly cancers, being the fourth leading
cause of cancer-related deaths. Long-term survival
reaching 15% is achieved in less than 5% of patients
who undergo surgery, and median survival is only 6
months in those with inoperable lesions. A deeper
understanding of PDAC biologic characteristics as
well as novel prognostic markers are therefore re-
quired to improve outcomes. Herein we report that
1524BAG3, a protein with recognized anti-apoptotic activ-
ity, was expressed in 346 PDACs analyzed, but was not
expressed in the surrounding nonneoplastic tissue.
In a cohort of 66 patients who underwent radical
resection (R0), survival was significantly shorter in
patients with high BAG3 expression (median, 12
months) than in those with low BAG3 expression
(median, 23 months) (P  0.001). Furthermore, we
report that BAG3 expression in PDAC-derived cell
lines protects from apoptosis and confers resistance
to gemcitabine, offering a partial explanation for the
survival data. Our results indicate that BAG3 has a
relevant role in PDAC biology, and suggest that BAG3
expression level might be a potential marker for pre-
diction of patient outcome. (Am J Pathol 2012, 181:
1524–1529; http://dx.doi.org/10.1016/j.ajpath.2012.07.016)
Pancreatic cancer is the fourth leading cause of cancer-
related deaths worldwide. Early symptoms of the disease
are extremely rare, and therefore it is diagnosed in more
than two-thirds of patients only when it is locally ad-
vanced and/or has metastasized. Consequently, the
overall 5-year survival rate among patients is 5%.1,2 At
present, the only chance for cure is radical surgical re-
section. The median survival in patients who have under-
gone resection and in whom the tumor is limited to the
pancreas (T1 and T2) is about 22.3 months, and in pa-
tients with cancer that extends outside the pancreas (T3)
is 15.5 months.3 Factors used to assess prognosis in-
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ence of lymph node metastases. High levels of the car-
bohydrate antigen 19–9 (CA 19–9) and its persistence
after surgery are negative prognostic indicators,2 and
additional markers have been proposed recently.4–6
BAG3 has previously been reported to be strongly
expressed in pancreatic tumor cells.7 The protein is a
74-kDa member of the co-chaperone BAG family and a
partner of heat shock protein 70, of which it modulates
the activities either positively or negatively, depending on
the context.8 Furthermore, through a WW domain and a
proline-rich repeat (PXXP), BAG3 can interact with other
proteins.8 Although its expression is constitutive in only a
few cell types, it can be induced in leukocytes and other
normal cells in response to stress. It is constitutively ex-
pressed in several tumors including leukemia, lym-
phoma, myeloma, thyroid carcinomas, glioblastomas,
and melanomas,9–15 in which several lines of evidence
suggest that it can sustain tumor cell survival. Indeed,
down-modulation of BAG3 in primary samples of B-cell
chronic lymphocytic leukemia and acute lymphoblastic
leukemia results in an increase in both basal and drug-
induced apoptosis.12–13 Recently, we have also reported
that BAG3 is strongly expressed in glioblastomas when
compared with the less aggressive astrocytomas and
that in these tumors it exerts an anti-apoptotic activity by
retaining BAX protein in the cytosol, thus preventing its
mitochondrial translocation.14 Furthermore, BAG3 over-
expression was observed in a subset of melanomas in
humans, with a significant increase in tumor cells in
lymph nodes and distant organ metastases.15 In the
present study, we investigated the expression of BAG3 in
a large cohort of PDACs, its correlation with survival, and
its potential role in response to gemcitabine.
Materials and Methods
Tumor Samples
Tumor samples were obtained from a series of unse-
lected patients who underwent surgical resection of
PDAC between January 10, 1992 and September 30,
2010 at the University of Verona (Verona, Italy), the NCI
“Fondazione G. Pascale” (Naples, Italy), the Department
of Surgery, Academic Medical Center (University of Am-
sterdam, the Netherlands), and IRCCS “Casa Sollievo
della Sofferenza” (San Giovanni Rotondo, Foggia, Italy).
Furthermore, we analyzed tissue samples from two tissue
microarrays, TMA No. 79560448 pancreatic cancer prog-
nosis (Cambridge Bioscience Ltd., Cambridge, UK) and
TMA PA2082 (US-Biomax, Inc., Rockville, MD), that con-
tained also normal pancreas tissue samples from 11 do-
nors (6 men and 5 women; mean  SD age, 44.6  19.3
years). Altogether, 346 tissue samples with histologically
proved PDAC (184 men and 162 women; age, 63  10.5
years) were available for immunohistochemical analysis.
For PCR analysis, 25 fresh-frozen tissue samples ob-
tained from patients who underwent surgery because of
pancreatic cancer were available. PDAC was ascer-
tained at histologic analysis in all 25 patients (21 men and4 women; age, 65.4  11.9 years). Clinical characteris-
tics of patients are given in Table 1.
Immunohistochemistry
The immunohistochemistry protocol included deparaffi-
nation in xylene, rehydration via decreasing concentra-
tions of alcohol down to pure water, non-enzymatic anti-
gen retrieval in citrate buffer (pH 6.0) for 30 minutes at
95°C, and endogenous peroxidase quenching with H2O2
in methanol for 20 minutes. After rinsing with PBS, the
samples were blocked using 5% normal horse serum in
0.1% PBS or bovine serum albumin. To detect BAG3,
samples were incubated for 1 hour at room temperature
with the monoclonal antibody AC-1 (BIOUNIVERSA SRL,
Salerno, Italy) at a concentration of 3 g/mL. After wash-
ing thoroughly with PBS, sections were incubated using a
biotinylated secondary anti-mouse IgG for 20 minutes,
then rinsed, incubated using avidin-biotin-peroxidase
complex (Novocastra; Leica Microsystems, Milan, Italy)
and developed using diaminobenzidine (Sigma-Aldrich
Corp., St. Louis, MO). Finally, the sections were counter-
stained using hematoxylin, dehydrated in alcohol,
cleared in xylene, and mounted using Permount (Fisher
Scientific, Inc., Milan, Italy).
Quantitative Real-Time RT-PCR
Tissue specimens of resected pancreatic cancer were
immediately frozen in liquid nitrogen and stored at80°C
until RNA extraction. Total RNA was isolated from frozen
tissues and from pancreatic cancer cell lines via phenol
extraction (TRIzol Reagent; Invitrogen Corp., Carlsbad,
CA). In tissue samples, cancer cellularity was enriched
via cryostat sectioning and dissection of most cellular
areas. RNA concentration and purity (A260:A280 2.0;
A260:A2301.8) were validated using a spectrophotom-
eter (NanoDrop; Thermo Fisher, Inc., Waltham, MA). One
microgram total RNA was reverse transcribed using a
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Inc., Foster City, CA) according to the man-
ufacturer’s instructions. A quantitative real-time PCR as-
say was used to assess the differential expression of
BAG3 in tumor tissue samples. Primers for the human
BAG3 mRNA were synthesized by Primm SRL (Milan,
Italy): forward primer, 5=-CCTGTTAGCTGTGGTTG-3=;
and reverse primer, 5=-AACATACAGATATTCCTATGGC-
3=. All quantitative PCRs were performed in a final volume
of 25 L, in 3 replicates per sample, using the QuantiFast
SYBR Green PCR kit (QIAGEN, Hamburg, Germany), and
run in an ABI PRISM 7700 Sequence Detection System
(Applied Biosystems) according to the following condi-
tions: 95°C for 5 minutes, 40 cycles at 95°C for 10 sec-
onds, and 60°C for 30 seconds. Data were acquired as
threshold cycle value using SDS software version 2.1. In
each sample, the BAG3 mRNA relative expression level
was obtained using the comparative method, after nor-
malizing for the expression of endogenous GAPDH (glyc-
eraldehyde-3-phosphate dehydrogenase).16
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The pancreatic cancer cell lines (MIA PaCa-2, AsPC-1,
PSN1, Capan-1, and PANC-1) were obtained from the
ATCC (Manassas, VA) cell bank. MIA PaCa-2 cells were
cultured in DMEM (Dulbecco’s modified Eagle’s medium)
and supplemented with 10% fetal bovine serum (FBS)
and 2.5% horse serum. AsPC-1 and PSN1 cells were
grown in RPMI 1640 medium supplemented with 10%
FBS. Capan-1 cells were cultured in RPMI 1640 medium
containing 20% FBS, and PANC-1 were cultured in
DMEM supplemented with 10% FBS. All media for the
above cell lines were purchased from Lonza (Bergamo,
Italy) or MediaTech (Manassas, VA), and were supple-
mented with 100 U/mL penicillin and 2 g/mL streptomy-
cin (Sigma-Aldrich Corp). Cells were incubated at 37°C in
a 5% CO2 environment, and were treated with gemcit-
abine [2=,2=-difluorodeoxycytidine (Gemzar; Eli Lilly Italia
SPA, Sesto Fiorentino, Italy)] at the indicated concentra-
tions.
Immunoblot Analysis
Cells were collected, washed in PBS, and resuspended in
RIPA buffer (pH 8) (150 mmol/L NaCl [pH 8], 50 mmol/L
Tris-HCl, 1% NP-40, 0.5% Na-Doc, and 0.1% SDS) and 1X
protease inhibitor cocktail (Roche Diagnostics, Milan, Italy)
for 30 minutes on ice. The lysates were centrifuged at
10,000  g for 10 minutes at 4°C, and the supernatant was
used for Western blot analysis. Protein concentration was
measured using the Bradford protein assay reagent
(Pierce, Celbio, Milan, Italy) using bovine serum albumin as
standard. Fifteen micrograms protein extracts was sub-
jected to electrophoresis via 10% SDS-PAGE, and electro-
blotted onto polyvinylidene difluoride membranes (Millipore
SPA, Milan, Italy). Membranes were then incubated for 1
hour at room temperature with blocking solution consisting
of 5% low-fat milk in Tris-buffered saline solution and Tween
20 [TBST; 100 mmol/L Tris (pH 7.5), 0.9% NaCl, and 0.1%
Tween 20], and probed overnight at 4°C using the rabbit
polyclonal antibody TOS-2 (1:5000 in blocking solution) or
with anti-GAPDH antibody (mouse monoclonal antibody;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Horserad-
ish peroxidase–conjugated IgG (1:8000 in blocking solu-
tion; Millipore) was used to detect specific proteins. Immu-
nodetection was performed using chemiluminescent
substrates, and was recorded using Hyperfilm ECL (both
Table 1. Analysis of Tumor Samples
Variable
No. of
patients
Age mean  SD,
year
Immunochemistry
Patients with PDAC 346 63.0 10.05
Patient survival 66 61.9  11.3
RT-PCR
Patients with PDAC 25* 65.4 11.9
*At RT-PCR, data for tumor grade differentiation were not available fo
ND, no data; PDAC, pancreatic ductal adenocarcinoma.from Amersham Pharmacia Biotech, Inc., Piscataway, NJ).Apoptosis
Cells were seeded in 24-well plates (1 104 cells per well)
and treated with various concentrations of gemcitabine
and/or transfected with BAG3 small-interfering RNA (siRNA)
or nontargeted siRNA (NTsiRNA) (see figure legends). At
the end of treatment, the percentage of sub-G0/G1 cells
was analyzed via propidium iodide incorporation into per-
meabilized cells, and flow cytometry was performed as
described previously.9 Data were analyzed using Student’s
t-test using the Prism statistical program (GraphPad Soft-
ware, Inc., San Diego, CA). Error bars depict SD. P  0.01
to 0.05 was considered significant; 0.001 to 0.01, very sig-
nificant; and 0.001, highly significant.
siRNAs and Transfections
A specific siRNA (5=-AAGGUUCAGACCAUCUUGGAA-
3=) targeting BAG3 mRNA and a control NTsiRNA (5=-
CAGUCGCGUUUGCGACUGG-3=) were purchased from
Dharmacon, Inc. (Lafayette, CO). Cells were transfected
with siRNAs at a final concentration of 200 nmol/L using
TransFectin (Bio-Rad Laboratories, Inc., Hercules, CA).
Statistical Analysis
Baseline characteristics of patients were reported as
mean  SD or as frequency and percentage for contin-
uous and categorical variables, respectively. Compari-
sons between low-positive and high-positive results were
made using Fisher’s exact test and the Mann-Whitney U
test for categorical and continuous variables, respec-
tively. BAG3 mRNA expression levels were reported as
median, with interquartiles (Q1 and Q3), and comparison
between different histologic types of pancreatic cancer
was assessed using the Mann-Whitney U-test. Associa-
tion analyses between BAG3 mRNA, expression and cat-
egorical and continuous clinical variables were per-
formed using the Mann-Whitney U test or Kruskal-Wallis
one-way analysis of variance and Spearman’s correlation
coefficient, respectively. Survival analyses were per-
formed using the Kaplan-Meier curve and Cox propor-
tional hazards models using commercially available soft-
Sex Local tumor stage no. (%)
Female T1 T2 T3 T4
165 5 (1.4) 59 (17.1) 264 (76.3) 18 (5.2)
30 0 1 (1.5) 65 (98.5) 0
4 2 (8.0) 3 (12.0) 20 (80.0) ND
(table continues)
5 patients.Male
181
36
21ware (release 13; SPSS, Inc., Chicago, IL).
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We analyzed PDAC samples from 346 patients (Table 1).
BAG3 staining revealed moderate positivity of the islets of
Langerhans, whereas normal pancreatic ducts and pan-
creatic acinar cells exhibited no BAG3 expression. This
Figure 1. BAG3 expression correlates with patient survival. A: Representa-
tive images of BAG3 low-positive and BAG3 high-positive tumor samples
stained using a monoclonal anti-BAG3 antibody revealed by using a biotin-
ylated secondary antibody. Sections were counterstained with hematoxylin.
Two different magnifications are shown: 100 (left panels) and 400
(right panels). B: Survival curves were made comparing 39 patients with
low BAG3 staining (40% of positive cells) with 27 patients with high BAG3
staining (40% of positive cells). Median survival increased from 12 months
in the high-positive group to 23 months in the low-positive group. (P 
0.001, log rank test). C: BAG3mRNA relative expression was evaluated using
quantitative RT-PCR. Values are given as mean  SD. The blue line repre-
sents the median value calculated. D: Survival analysis was made for all
patients analyzed using quantitative RT-PCR. In 13 patients with high BAG3
Table 1. Continued
Node stage no. (%)
N0 N1
130 (37.6) 216 (62.4) 1
13 (19.7) 53 (80.3)
6 (24.0) 19 (76.0)expression, survival was shorter (median, 19.0 months) than in 12 patients
with low BAG3 expression (median, 32.0 months) (P  0.02, log rank test).was true in both normal pancreas and non-neoplastic
pancreatic tissue adjacent to the tumor mass. BAG3
staining was observed predominantly in the cytoplasm of
tumor cells. The intensity of staining of BAG3 was vari-
able, as was the number of positive cancer cells.
We assigned a score based on the percentage of
positive cancer cells in the sample by counting the num-
ber of positive cells over the total cancer cells in 10
non-overlapping fields using 400 magnification. The
median percentage of BAG3-positive cells, calculated as
described, was 40%, and this value was used as the
cut-off to differentiate low- and high-positive samples. On
the basis of this classification, 190 patient samples (55%)
were classified as low positive (40% of positive cells),
and 156 (45%) were classified as high positive (40% of
positive cells) (Figure 1A). More than 75% and 90% of
analyzed tumors were, respectively, stage T3 and grade
G2/G3 (Table 1). There was no significant correlation
between high or low BAG3 positivity and tumor stage or
grade (data not shown). Survival analysis was performed
in 66 patients, and all lesions examined had resection
margins free of tumor cells (R0), and only 3.7% had
metastasized to distant organs (Table 1). In patients with
high BAG3 expression, survival was significantly shorter
(median, 12.0 months) than in those with low BAG3 ex-
pression (median, 23.0 months) (P  0.001) (Figure 1B).
On the basis of Cox proportional analysis, high BAG3
expression was associated with a greater than twofold
higher risk of death (Table 2).
The immunohistochemical data on BAG3 expression
was also confirmed measuring BAG3 mRNA levels in 25
PDAC tissue samples (Table 1). In particular, at the time
Table 2. Multivariate Cox Regression Analysis
Variable HR 95% CI P value
Age, year 0.99 0.97–1.02 0.60
Sex, M/F 0.86 0.48–1.55 0.62
Tumor grade, G2 vs. G1 0.84 0.24–2.98 0.79
Tumor grade (G3 vs G1) 1.55 0.45–5.37 0.49
Local tumor stage, T3 vs T2 2.5 0.30–21.17 0.400
Node stage, N1 vs N0 1.17 0.58–2.37 0.67
BAG3 positivity, high vs low 2.7 1.53–4.78 0.001
death events  66
n TOT  66
F, female; M, male; CI, confidence interval; HR, hazard ratio.
Tumor grade no. (%)
G2 G3
177 (51.2) 153 (44.2)
37 (56.1) 26 (39.4)
) 13 (54.2) 8 (33.3)G1
6 (4.6)
3 (4.5)
3 (12.5Bold indicates underlining results from different BAG3 positivity
groups.
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had died of pancreatic cancer progression. The median
of expression of BAG3 mRNA in tumors analyzed was set
at 0.007 (Q1  0.004; Q3  0.01) (Figure 1C). All of the
considered demographic and clinical features in patients
with PDAC were unrelated to BAG3 mRNA levels. Thus,
correlation with survival was evaluated, and the median
BAG3 expression in PDAC samples was used as a cutoff
to differentiate patients with low versus high BAG3 ex-
pression. Thirteen samples (52%) were thus classified as
high BAG3 positive, and 12 samples (48%) as low BAG3
positive. Patients with high BAG3 expression had shorter
survival (median, 19.0 months) than did those with low
Figure 2. Down-regulation of BAG3 sensitizes PDAC cell lines to gemcit-
abine. A: Pancreatic cancer cell lines (PSN1, Capan-1, AsPC-1, PANC-1, and
MIA PaCa-2) were treated using various concentrations of gemcitabine. After
48 hours, apoptotic cell death was analyzed (see Materials and Methods).
Graph depicts mean  SD percentage of sub-G0/G1 cells. Data are repre-
sentative of three independent experiments. B: Western blot analysis of
BAG3 in pancreatic cancer cell lines; GAPDH housekeeping protein contents
were used to monitor equal loading conditions. C: MIA PaCa-2 and PANC-1
cell lines were treated using 2 mol/L gemcitabine (GEM) for the indicated
times. BAG3 protein expression levels were monitored using Western blot
analysis, and BAG3mRNA levels were analyzed using RT-PCR (D); the graph
depicts relative BAG3 mRNA levels ( SD), and data are representative of
three independent experiments. E: MIA PaCa-2 and PANC-1 cell lines were
transfected with BAG3 siRNA or a nontargeted siRNA (NTsiRNA) for 72
hours, then treated with 2 mol/L gemcitabine (GEM) for 24 hours. BAG3
levels were analyzed using Western blotting, and GAPDH levels were de-
tected to monitor equal loading conditions. F: MIA PaCa-2 and PANC-1 cells
were transfected as described above, and treated with 2 mol/L gemcitabine
(GEM) for 24 or 48 hours. Apoptotic cell death was analyzed (see Materials
and Methods). Graph depicts mean  SD percentage of sub-G0/G1 cells.
Data are representative of three independent experiments.BAG3 expression (median, 32.0 months) (P  0.02) (Fig-ure 1D). On the basis of Cox proportional analysis, high
BAG3 expression was associated with a greater than sixfold
higher risk of death (univariate analysis: hazard ratio, 6.09;
95% confidence interval, 1.11–33.60; P  0.04).
The first-line chemotherapy for treatment of pancreatic
cancer is gemcitabine. 17 To investigate the role of BAG3
protein in response to gemcitabine, we analyzed the lev-
els of BAG3 protein in pancreatic carcinoma cell lines
with various degrees of sensitivity to the drug (Figure
2A).18–21 The cell lines express very different levels of
BAG3 (Figure 2B); however, no correlation between
these and sensitivity to gemcitabine can be made. Gem-
citabine significantly induced BAG3 expression in all cell
lines tested, at both the protein and mRNA levels (Figure
2, C-D). We therefore tested two of the cell lines with
intermediate sensitivity to gemcitabine and very different
levels of BAG3 (MIA PaCa-2 and PANC-1) to determine
whether down-regulation of BAG3 sensitized cells to
gemcitabine. To this end, we transfected both cell lines
with a specific siRNA that targeted BAG3 mRNA or with a
nonspecific NTsiRNA, and treated cells with gemcitabine
for the indicated times. Silencing of BAG3 alone induced
cell death in both cell lines, and treatment with gemcitabine
resulted in a significant increase in cell death that reached
70% in the MIA PaCa-2 cell line (Figure 2, E–F). These data
clearly show that BAG3 is a survival factor for pancreatic
cancer cells and that its down-regulation when combined
with gemcitabine can contribute to their eradication.
Discussion
Pancreatic ductal adenocarcinoma is one of the most
deadly cancers because of its aggressiveness and re-
sistance to current therapies. Identification of novel prog-
nostic markers that will enable better classification of
patients and better knowledge of the tumor biology are
mandatory if we hope to improve survival. BAG3 is over-
expressed both at the protein and mRNA levels in pan-
creatic adenocarcinomas, and, more important, high ex-
pression levels are associated with a greater risk of death.
Markers that can identify patients with resection margins
free of tumor cells (R0), with a better prognosis, are required
for assistance in making therapeutic choices. In this re-
spect, it is interesting that in a homogeneous set of R0
samples, BAG3 expression inversely correlated with patient
survival. Patients with tumors that expressed low positivity of
BAG3 expression had significantly (P  0.001) longer sur-
vival (median, 23 months) than did patients with tumors that
expressed high levels of the protein (median, 12 months).
Similarly, although in a smaller cohort of patients, survival
was inversely correlated with BAG3 mRNA levels.
In addition, BAG3 down-modulation enhances apop-
tosis in PDAC cell lines, which supports the theory that
BAG3 up-regulation is important to survival of pancreatic
cancer cells and contributes to their pathogenesis. We
and others have previously reported increased BAG3
expression in various tumors.9,11–15 In all tumors studied
to date, however, only some were positive for BAG3 ex-
pression, with the highest percentages reached in mela-
nomas (71%)15 and glioblastomas (88.9%).14 In the pres-
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again suggesting that this alteration may have a role in
the biology of this tumor. This is probably linked to the
ability to act as an important survival factor for tumor
cells. This is consistent with previous studies that found
that BAG3 exerts an anti-apoptotic activity via multiple
mechanisms. We have previously reported that in mela-
noma cells, BAG3 protects cells by increasing NF-B
activation,9 whereas in glioblastomas, it does so by se-
questering BAX protein in the cytosol, thus preventing
activation of the intrinsic apoptotic pathway.14 It therefore
seems that BAG3, because of its multifaceted ability to
complex with many proteins, can regulate different fac-
tors depending on the specific cell context, however al-
ways resulting in increased survival of the cell.14 We also
found that gemcitabine induces BAG3 up-regulation, and
this can possibly contribute to survival of cells undergo-
ing treatment. BAG3 regulation by gemcitabine seems to
be at the mRNA level. This could depend on the reported
ability of gemcitabine to up-regulateWT1,22 which in turn
binds and activates BAG3 promoter.23
In conclusion, our results show that BAG3 is overex-
pressed in PDAC samples and that in samples from
patients who have undergone radical resection, low
expression of the protein evaluated either via immuno-
histochemistry or PCR correlates with higher survival. Fur-
thermore, since BAG3 down-modulation results in in-
creased death of pancreatic cancer cells alone or in
combination with gemcitabine in vitro, the relation of this
marker with patient response to therapy seems worthy of
investigation. Because of its wide expression in all of the
lesions tested and its involvement in sustaining pancreatic
cancer cell survival, BAG3 could represent a valuable tar-
get for innovative therapies in PDAC.
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